News

Based on this review classification, the FDA has issued an action date for the NDA of 5 June 2012 under the Prescription Drug User Fee Act (PDUFA). Salix

Under the agreement, the cross-royalty rates were reduced and commercial rights for certain territories were changed. Sobi will have commercial rights in Europe, Russia, Turkey and certain countries

Liposomal Grb-2 is indicated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).

Mylan has acquired the abbreviated new drug application (ANDA) of the generic version of Valeant’s BenzaClin, Clindamycin Phosphate / Benzoyl Peroxide Gel. Mylan also has purchased a license

Vorapaxar, an investigational oral Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist, is being developed for the prevention of thrombosis, thereby reducing cardiovascular death (CVD). TRA-2P study demonstrated

The approval is backed by results from a randomized withdrawal study designed to assess the efficacy of Vyvanse in adults aged 18 to 55 years who were receiving

XanoLean, a nutrient-rich, botanical formula works as a appetite suppressant producing a completely satisfied feeling while eating less food, the company said. The natural product does not produce

The RX-04 program is focused on using a novel binding site within the ribosome to develop new classes of antibiotics to treat some of the multi-drug resistant Gram-positive

The company sales for the twelve months of 2011 are approximately $21,000,000, which is an increase of 425%, compared to all of 2010 sales of $4,000,000, the company